<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the atazanavir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
<ATC code="N07BC51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD04" />
<ATC code="A02BD05" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE  " rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
<ATC code="J05AR06" />
<ATC code="J05AR08" />
<ATC code="J05AR09" />
<ATC code="J05AR03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Do not administer atazanavir with the tenofovir without ritonavir</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the atazanavir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
<ATC code="N07BC51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD04" />
<ATC code="A02BD05" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE  " rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
<ATC code="J05AR06" />
<ATC code="J05AR08" />
<ATC code="J05AR09" />
<ATC code="J05AR03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Do not administer atazanavir with the tenofovir without ritonavir</COMMENT>
</INTERACTION>
</INTERACTIONS>
